Is Catalyst Pharmaceuticals (CPRX) overvalued or fairly valued?

MarketChacha shows Catalyst Pharmaceuticals's valuation in context — a trailing P/E of about 17.7, a forward P/E of about 9.0, a price-to-book of about 3.8 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Catalyst Pharmaceuticals's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.32×) from reported figures — education, not a rating.

What is Catalyst Pharmaceuticals's revenue?

Catalyst Pharmaceuticals reported revenue of $589.0M for FY2025, with net profit of $214.3M, per official filings.

What is the share price of Catalyst Pharmaceuticals (CPRX)?

Catalyst Pharmaceuticals last traded at $31.49, as of 7/14/2026 — a delayed quote shown for education, not investment advice.

Catalyst Pharmaceuticals

CPRX · NYSE · Healthcare · United States

Snapshot

TickerCPRX

ExchangeNYSE

SectorHealthcare

IndustryBiotechnology

CountryUnited States

Employees182

HeadquartersCoral Gables, United States

Websitecatalystpharma.com

Filings tracked22

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Who owns it

Insiders5.6%
Institutions90.0%
Public & other4.4%

531 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.15.34%
State Street Corporation5.61%
Vanguard Capital Management LLC4.18%
American Century Companies Inc3.38%
Deerfield Management Company, L.P3.22%
Dimensional Fund Advisors LP2.80%
Bank of America Corporation2.48%
Geode Capital Management, LLC2.43%

Largest institutional holders — last updated 3/31/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.32×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend17.9% → 36.4%

Margin has expanded by about 18.5 points — the business is getting more profitable.

Return on equity22.5%

Latest ROE of 22.5% — capital is generating a healthy return.

Growth qualityrev 22% · PAT 73%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $162.1M · EPS 0.82

Est. earnings growth +20.4%

Next fiscal year

Rev $717.9M · EPS 3.18

Est. earnings growth +0.2%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$589.0M

Net margin

36.4%

ROE

22.5%

Revenue CAGR (2y)

+21.6%

Profit CAGR (2y)

+73.2%

EPS (FY2025)

1.68

Net profit (FY2025)

$214.3M

Ask MarketChacha about CPRX

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$589.0M	$214.3M	1.68	36.4%	22.5%
FY2024	$491.7M	$163.9M	1.31	33.3%	22.5%
FY2023	$398.2M	$71.4M	0.63	17.9%	18.4%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$149.4M	$63.7M	0.50	42.7%
2025Q3	$148.4M	$52.8M	0.42	35.6%
2025Q2	$146.6M	$52.1M	0.41	35.6%
2025Q1	$141.4M	$56.7M	0.45	40.1%
2024Q3	$128.7M	$43.9M	0.35	34.1%
2024Q2	$122.7M	$40.8M	0.33	33.2%
2024Q1	$98.5M	$23.3M	0.19	23.6%
2023Q3	$102.7M	$-30.8M	-0.29	-30.0%
2023Q2	$99.6M	$37.8M	0.33	37.9%
2023Q1	$85.4M	$29.6M	0.26	34.6%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Completion of acquisition/disposition, Delisting notice, Security holder rights, Change in control, Executive/director change, Bylaw/charter change, Exhibits
SEC7/16/2026material
8-K — Executive/director change, Shareholder vote results
SEC7/8/2026material
8-K — Other events, Exhibits
SEC6/30/2026material
8-K — Other events
SEC6/23/2026material
10-Q filing
SEC5/11/2026
8-K — Other events, Exhibits
SEC5/11/2026material
8-K — Material agreement, Bylaw/charter change, Reg FD disclosure, Other events, Exhibits
SEC5/7/2026material
10-K/A filing
SEC4/30/2026
8-K/A — Other events
SEC3/19/2026
8-K — Other events
SEC3/18/2026material
10-K filing
SEC2/25/2026
8-K — Other events, Exhibits
SEC2/25/2026material
8-K — Reg FD disclosure, Exhibits
SEC1/12/2026material

2025

10-Q filing
SEC11/5/2025
8-K — Other events, Exhibits
SEC11/5/2025material
8-K — Other events, Exhibits
SEC10/1/2025material
8-K/A — Exhibits
SEC8/28/2025
8-K — Other events, Exhibits
SEC8/25/2025material
8-K — Other events, Exhibits
SEC8/7/2025material
10-Q filing
SEC8/6/2025
8-K — Other events, Exhibits
SEC8/6/2025material
8-K — Executive/director change, Exhibits
SEC8/4/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.